The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.

Stinchcombe, MD. The promising data from the phase I trial led to initiation of the phase II HERTHENA-Lung01 trial of HER3-DXd once every 3 weeks in patients with EGFR-mutated NSCLC who had previously ...

As a condition of using these data, you must cite the use of this data set. Such a practice gives credit to data set producers and advances principles of transparency and reproducibility. Other ...

The antihistamine desloratadine displays a two-step, reversible single-crystal to single-crystal phase transition during heating/cooling cycles between three conformational polymorphs: the low ...

Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC). This is ...